Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
Urszula Wojtyra’s articles from Smart & Biggar are most popular:
within Food, Drugs, Healthcare and Life Sciences topic(s)
As previously reported, the
Canadian Agency for Drugs and Technologies in Health (CADTH)
and the Pan-Canadian Formulary Advisory Panel (Panel) held an
information session on January 18 about a potential pan-Canadian
formulary.
On January 11, CADTH posted a discussion
paper about the proposed framework for a potential
pan-Canadian formulary, which includes a discussion of the proposed
principles, values, and criteria to guide the development as well
as a proposed sample list of drugs focusing on commonly prescribed
drugs and related products in three therapeutic areas
(cardiovascular disease, diabetes, and psychiatric illness).
CADTH has provided an online
questionnaire for stakeholders to provide feedback;
the online consultation period will run through
to February 25, 2022.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
